LifeStance Health Group, Inc. (LFST) fair value analysis
Nasdaq · Updated 2026-10-19
LFST price how computed
Valuation status
Awaiting full valuationLFST does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under our standards.
We require at least six validated trailing price-to-earnings windows before publishing one. TickrTrends re-evaluates every covered stock weekly; a verdict publishes automatically once enough validated history accumulates.
- Last price
- $11.74
- Sector
- Healthcare
- 12-month range
- $4.81–$13.38
- Market cap
- $4.46B
- From 52-week high
- -12.3%
- Shares outstanding
- 380M
- Rank in Healthcare by quality score
- #40 of 301
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
LifeStance Health Group, Inc. is a healthcare company that provides behavioral health services, including psychiatry, therapy, and other mental health treatments through a combination of in-person and telehealth delivery methods. The company operates across multiple states in the United States, serving patients through its network of clinicians and treatment centers.
LFST currently ranks #40 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $4.46B
- P/E (trailing)
- 51x
- Revenue (TTM)
- $1.58B
- Net margin
- 3.2%
- EPS (TTM)
- $0.23
- Gross margin
- 35.2%
- Debt / equity
- 0.14
- Revenue growth (3-yr avg)
- 21.9%
- Shares outstanding
- 380M
Derived indicators how computed
- Quality grade
- A
- Margin trend
- Stable
- 52-week position
- The top quarter of its range
Technicals how computed
- RSI (14-day)
- 35 · neutral
- 50-day average
- $12.34
- 200-day average
- $9.06
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-11-05
- Last 8 quarters vs consensus
- 7 beat, 1 missed
- Quarter by quarter
- 2026-06 ▲ beat (+100.0%)
2026-03 ▲ beat (+16.7%)
2025-12 ▲ beat (+64.4%)
2025-09 ▼ miss (-75.0%)
2025-06 ▲ beat (+66.7%)
2025-03 ▲ beat (+400.0%)
2024-12 ▲ beat (+73.9%)
2024-09 ▲ beat (+400.0%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 9 buy · 2 hold · 0 sell (11 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $14.4
- Target vs last price
- +22.7%
What our data shows for LFST
- Our model validated 5 trailing price-to-earnings windows for LFST, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $4.81–$13.38.
- The 14-day relative strength index sits at a neutral 35.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- LFST's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent LFST news
TickrTrends' derived news-sentiment signal for LFST is currently leaning positive, computed from recent coverage.
- A Look at LifeStance Health Group Inc (LFST) After 3.8% Gain -- GF Value $8.88 vs Price $12.22 (gurufocus.com, 2026-10-21)
- LifeStance Health Group Inc (LFST) Shares Fall 5.1% -- GF Value Says Still Overvalued (gurufocus.com, 2026-10-17)
- LifeStance to Host Third Quarter 2026 Earnings Conference Call on November 5, 2026 (manilatimes.net, 2026-10-15)
More LFST news
- LifeStance Health Group Inc (LFST) Shares Surge 3.3% -- What GF Score of 81 Tells Investors (gurufocus.com, 2026-10-06)
- LFST Maintained by Keybanc -- Price Target Raised to $15.00 (gurufocus.com, 2026-10-05)
- LifeStance Health Group Inc (LFST) Stock Down 3.8% but Still Overvalued -- GF Score: 51/100 (gurufocus.com, 2026-09-23)
What people are saying
Follow the LFST conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — TickrTrends' derived indicators for LFST showed a shift in trend momentum this week. The 50/200-day trend state moved from an uptrend to a mixed state, suggesting less directional clarity in the stock's recent price action. The valuation assessment remains pending full analysis.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — LFST in the Healthcare sector showed movement in its trend indicators this week, with the 50/200-day trend state shifting from mixed to uptrend. The current valuation verdict for LFST remains awaiting full valuation according to TickrTrends' derived indicators.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends' derived indicators for LFST showed notable shifts this week. The 50/200-day trend state transitioned from an uptrend to a mixed state, while momentum declined from an A rating to none. LFST operates within the Healthcare sector and remains at an awaiting full valuation verdict.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is LFST stock undervalued?
LFST does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under TickrTrends' standards; it is re-evaluated every week.
What is LFST's TickrTrends verdict?
LFST is currently marked 'Awaiting full valuation' - a verdict publishes automatically once at least six validated trailing P/E windows accumulate.
How does LFST compare to other Healthcare stocks?
LFST ranks #40 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is LFST overbought or oversold?
LFST's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does LFST report earnings next?
LFST's next earnings report is scheduled for 2026-11-05, per the published earnings calendar.
Does LFST usually beat earnings estimates?
Over its last 8 reported quarters LFST beat the consensus estimate 7 times and missed 1 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about LFST?
Of 11 analysts covering LFST, 9 rate it a buy, 2 a hold and 0 a sell - buy-leaning, with a consensus price target of $14.4 (+22.7% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.